Dr. Harvey Wong is an Associate Professor of Pharmacokinetics in the Faculty of Pharmaceutical Sciences. He obtained his B.Sc. in pharmacy, and Ph.D. in pharmacokinetics and biopharmaceutics at UBC. Following graduation, Dr. Wong was employed in pharmaceutical industry at the DuPont Pharmaceuticals Company, Bristol-Myers Squibb, and most recently at Genentech in the areas of oncology, neuroscience, and immunology. At Genentech, he served as a research project team leader, a non-clinical development team leader, and gained extensive experience in regulatory filings. Most notably, Dr. Wong was part of the team involved in the development of vismodegib (Erivedge®), the first in class hedgehog pathway inhibitor, which was awarded the "Drug Discovery of the Year" award in 2012 by the British Pharmacological Society.
Dr. Wong's expertise is in drug discovery and development strategies with a specialization in ADME, pharmacokinetics, and modeling and simulation (translational PK/PD analysis, systems pharmacology, and physiologically based pharmacokinetic modeling). He currently chairs the PK/PD Discussion Group for the IQ Consortium and serves on the Editorial Board of Biopharmaceutics and Drug Disposition.
Dr. Harvey Wong's research interests include applications of translational modeling and simulation techniques to optimize drug dose and regimen for new therapeutics, and to better understand emergence of cancer tumor drug resistance.
"Drug Discovery of the Year Award." Graham RA, Wong H, Hop C, Gould S, de Sauvage F, Low J, Colburn D, Jin J, Dresser M, Joshi A, Lum B, Chang I, Mackey H, Roth I. The British Pharmacological Society. December 19, 2012.
"Physiologically-based Pharmacokinetic Modeling: Overview and Applications." Wong H. Pharmaceutical and BioScience Society – San Francisco Bay Workshop: Physiologically Based PK (PBPK) Modeling: Overview, Applications, Regulatory Opinions and Software Demo, Foster City, CA, USA. April 24, 2015.
"The Role of Preclinical Pharmacokinetic/ Pharmacodynamic Analysis in the Discovery and Development of Vismodegib." Wong H. Applied Pharmaceutical Analysis - India 2015 organized by the Boston Society, Mumbai, India. February 22-25, 2015.
"Translational Pharmacokinetic/ Pharmacodynamic Analysis as a Tool to Discover New Medicines." Wong H. 7th International Symposium on Drug Metabolism and Pharmacokinetics organized by the National Institute of Pharmaceutical Education and Research S.A.S. Nagar, NIPER, Mohali, India. February 18-21, 2015.
"From Mouse to Man and Back: Translational Pharmacokinetic-Pharmacodynamic Modeling in Oncology." Wong H. 2013 Gordon Research Conference on Drug Metabolism (Applications of PK-PD and TK-TD in Drug Discovery and Development Session), Holderness, NH, USA. July 7-12, 2013.
"Improving the Predictive Power of Preclinical Tumor Models Through Translational Pharmacokinetic-Pharmacodynamic Analysis." Wong H. CPSA Shanghai 2013: Reviving Pharmaceutical R&D with Translational Science, Regulatory Efficiency, and Innovative Models, Shanghai, China. April 24-27, 2013.